Tocilizumab, a humanized anti-IL-6R monoclonal antibody used primarily for rheumatoid arthritis and cytokine release syndrome, may also be a therapeutic option for BD due to elevated IL-6 levels in BD patients. The gene discussed is IL6R; the disease is Behcet disease.